Analysis of the Best Timing for Applying Tirofiban in PCI Operation for the Patients with ST Segment Elevation Myocardial Infarction

• Authors: Zhang Lei , Zhong Xiaoming , Hong Yan , Zhong Xiao Ming
• Languages of publication: EN

Abstracts

EN

This study is a comparative analysis of the best timing for applying tirofiban in the PCI emergency treatment for STEMI patients. We selected 109 patients with ST-segment elevation myocardial infarction from October 2013 to October 2014 and divided them into two groups, the early treatment group (53 cases) received tirofiban during the operation and the later treatment group (56 cases) received tirofiban after operation. The analysis was then conducted. Results: The proportion of IRA forward flow in TIMI2-3 for the 1st group during the radiography was higher than 2nd group, 50 cases with TIMI3 blood flow and 52 cases with TIMI3 blood flow in later treatment group. Comparing the TIMI3 flow of both groups, the difference was not statistically significant; for the CK-MB 4h and 8h after operation as well as the LVEF after operation, the differences are were not statistically significant. The occurrence rate of hemorrhage complication was low for both groups. The early use of tirofiban can make the thrombus fully dissolve and coronary blood flow remains in a good state, which is not only beneficial for myocardial perfusion but also helpful for deciding the length and side branch situation of coronary artery pathological changes.

Keywords

EN

PCI; MI; tirofiban; treatment timing

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2014
• Volume: 10
• Issue: 1

Dates

published

1 - 1 - 2015

accepted

15 - 10 - 2015

online

17 - 12 - 2015

received

29 - 6 - 2015

Contributors

author

Zhang Lei

• Cardiovascular Department of Huaihe Hospital of Henan University 475000, China

author

Zhong Xiaoming

• Cardiovascular Department of Huaihe Hospital of Henan University 475000, China

author

Hong Yan

• Cardiovascular Department of Huaihe Hospital of Henan University 475000, China

author

Zhong Xiao Ming

• Cardiovascular Department of Huaihe Hospital of Henan University 475000, China

References

• [1] Hao Z., Weijian H., Gaojun W., et al., The Effect of Intracoronary Tirofiban Treatment on Acute Myocardial Infarction with ST Segment Elevation, J. Prevention and Treatment of Cardia- Cerebral -Vascular Disease., 2011, 11(3), 4-6
• [2] Dongxing M., Huiliang L., Hongying Y., et al., Effects of Intracoronary Tirofiban Injection on Myocardial Perfusion and Near-Future Cardiac Function in STEMI Patients in Emergency Percutaneous Coronary Artery Intervention, J. Chinese General Practice., 2010, 5, 476-478
• [3] Weidong J., Yanbin L., Pengfei W., Effects of Tirofiban Hydrochloride on the Function of Left Ventricular and Prognostic Impact on STEMI Patients after PCI Treatment, J. China Medicines, 2011, 6(1), 25-27
• [4] Yan H.B., Li S.Y., Song L., et al., Thrombus aspiration plus intra-infarct-related artery administration of tirofiban improves myocardial perfusion during primary angioplasty for acute myocardial infarction, J. Chin Med J (Engl)., 2010, 6123(7), 877-883
• [5] Yong Z., Meiqin T., Jin L., Systematic Evaluation of the Effects of Domestic Tirofiban for Interventional Therapy in Chinese STEMI Patients, J. Chinese Journal of cardiovascular Rehabilitation Medicine, 2012, 21(1), 51-55
• [6] Jian W., Yansheng H., Jinghan W., et al., Effects of Tirofiban Applied in Various Ways for Blood Perfusion in STEMI Patients, J. Chinese Practical Diagnosis and Therapy, 2012, 26(7), 653-655
• [7] Limin X., Influence on the Activation of Systemaic Fibrinolysis in STEMI Patients Treated by Early Use of Tirofiban, D. Zhengzhou University, 2011
• [8] Miao W., Moshui C., Bo X., Zijun D., Dehong L., Effects Observation of Tirofiban On STEMI Patients Undergoing PCI, J. China Tropical Medicine, 2012, 08, 981-983
• [9] Cuijuan H., Ping L., Jianting G, Xiangwen L., Jian C., ZhengdongW., Clinical Efficacy and Safety of Half Dose of Tirofiban for Percutaneous Coronary Intervention in Elderly STEMI Patients, J. The Journal of Practical Medicine, 2014, 17, 2833-2835
• [10] Zhihua W., Jinfa J., Huigen J., et.al., Effects of Different Doses of Tirofiban on Peperfusion and Clinical Outcomes in the Patients with ST. Elevation Myocardial Infarction, J. Shanghai Med J., 2011, 34(5), 371-374
• [11] Xinshun G., Xiaoping G., Xinwei J., et al., Curative Effect Observation of AMI Patients Undergoing Delayed PCI in Combination with GPIIb/IIIa Receptor Antagonist, J. Chinese Journal of Gerontology, 2011, 31(9), 1530-1533
• [12] Azar R.R., Badaou G., Sarkis A., et al., Effect of high bolus dose tirofiban on the inflammatory response following percutaneous coronary intervention, J. Clin Cardiol, 2010, 33(1), E14-E19[Crossref]
• [13] Xiaozhong Z., Hong W., Jun Z., et al., Clinical Efficacy and Safety of Low-Dose of Tirofiban in Percutaneous Coronary Interventional Treatment of the Patients with Acute Coronary Syndrome, J/CD. Chinese Journal of Clinicians: Electronic Edition, 2012, 6, 1117-1120
• [14] Xuechao W., Predictive Factors for Myocardial Malperfusion after Primary Percutaneous Coronary Intervention in STEMI and Protective Effect of Tirofiban and Anisodamine, D. Hebei Medical University, 2012
• [15] Deibele A.J., Jennings L.K., Tcheng J.E., et al., Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intraecronary Eptifibatide (ICE) Trial, J. Circulation, 2010, 121(6), 784-791
• [16] Dominguez-Rodriguez A., Abreu-Gonzalez P., Avanzasc P., et al., Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention-Effects on soluble CD40ligand concentrations, J. Atherosclerosis, 2009, 206(2), 523-527[WoS]

Identifiers

DOI

10.1515/med-2015-0065